Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ludwig-Oxford Symposium on Cancer Early Detection and Epigenetics – a recap

Rittscher Shi Song

On 28-29th April 2021, we heard the latest developments from international leaders in these fields from the University of Oxford, Ludwig Cancer Research and beyond.

Understanding cell organisation in the human stomach


Dr Francesco Boccellato investigates how growth factors influence differentiation and patterning in human gastric glands.

New method for cost-effective genome-wide DNA methylation analysis


Dr Chunxiao Song’s team build on its TAPS method to develop an alternative to costly whole-genome sequencing for the detection of DNA methylation.

Vacancy: Postdoctoral Research Scientist – Cancer Immunology

Jobs Shi Van den Eynde

Grade 7: Salary in range £32,817 - £40,322 per annum (with discretionary range to £44,045)

Vacancy: Postdoctoral Research Scientist in Stem cells and 3D culture models

Boccellato Jobs

Grade 7: Salary in range £32,817 - £40,322 per annum

Ludwig Oxford researcher presents at the Oxford Immunology Symposium

Moura Alves

Dr Pedro Moura Alves described how the aryl hydrocarbon receptor senses bacteria to fine-tune the body’s response to infection

HIFs inhibit SARS-CoV-2 infection of lung epithelial cells


Activation of hypoxia inducible factors (HIFs) by either hypoxia or drug treatment inhibits SARS-CoV-2 entry and replication in lung epithelial cells, raising the potential of using clinically licensed HIF activators to prevent and/or treat COVID-19.

Improving immunotherapy


Professor Yang Shi’s group uses combination therapy to eradicate tumours that previously responded poorly to immunotherapy

Investigating infection-associated stomach cancer


A new review from the Boccellato lab describes the experimental models for studying the stages from Helicobacter pylori infection to carcinogenesis.

New method for studying AhR interactions

Moura Alves

Dr Pedro Moura Alves has developed a microscale thermophoresis-based approach for rapidly and robustly analysing aryl hydrocarbon receptor interactions.

Developing a system to simultaneously detect genetic and epigenetic information


Dr Benjamin Schuster-Böckler wins funding to develop algorithms that can identify both genetic variation and DNA methylation from the same sequencing data, with applications in biomedical research and detection of diseases such as cancer.

Understanding how inherited and acquired mutations interact to affect cancer

Germline and somatic variants in the p53 pathway cooperate to influence cancer risk, progression and response to therapy.

Celebrating 100 years of women in Oxford Medical Sciences

Ludwig Oxford Director Professor Xin Lu features in this showcase of women in diverse roles across Oxford’s Medical Sciences Division.

How to make blood vessels different

De Val

Professor Sarah De Val, Dr Alice Neal and Dr Svanhild Nornes investigate the role of ETS factors in blood vessel specification.

The role of Met1-linked ubiquitin signalling in inflammation and infection


Professor Mads Gyrd-Hansen reviews the current knowledge about this important post-translational modification.

Novel mechanism of repressive chromatin regulation in mammals


Professor Yang Shi uncovers a new role for RNA methylation and the RNA methyltransferase METTL3 in the maintenance of heterochromatin

New sequencing methods for distinguishing DNA modifications


Dr Chunxiao Song’s team have expanded their suite of bisulphite-free DNA modification sequencing methods to specifically and directly detect each of the four modifications made to the DNA base cytosine

Cancer epigeneticist Stephen B. Baylin joins Ludwig Oxford as a Visiting Professor

Ludwig Oxford welcomes this leading international figure in the field of cancer epigenetics

Drugging p53


The drug arsenic trioxide can restore the structure and function of some p53 tumour suppressor mutants, with potential as a future personalised cancer treatment strategy.

Q&A with Yang Shi

Ludwig Oxford’s newest recruit is interviewed in the latest edition of the Ludwig Link.

Load More